Comparison of antibody responses after DLI
Gene product . | Patient . | Pre-BMT . | Pre-DLI . | 2 mo . | 4 mo . | 6 mo . | 1 y . | 2 to 2.6 y . |
|---|---|---|---|---|---|---|---|---|
| DHA | 2, ER | - | - | ++ | ++++ | +++ | +++ | ++ |
| DHA | 5, LR | - | - | - | - | + | ++ | ++ |
| BCMA | 2, ER | - | - | + | ++++ | +++ | ++ | + |
| BCMA | 5, LR | - | - | - | - | + | + | + |
| FLJ10330 | 2, ER | - | - | + | +++ | ++ | + | + |
| FLJ10330 | 5, LR | - | - | - | + | + | ++ | + |
| Homer-3 | 1, ER | - | - | NA | ++ | ++ | ++ | + |
| Homer-3 | 7, LR | - | - | NA | - | + | ++ | + |
| ROCK-1 | 4, LR | - | - | - | - | - | + | ++++ |
| ROCK-1 | 5, LR | - | - | - | - | + | + | + |
| ROCK-1 | 2, ER | - | - | + | +++ | ++ | + | + |
| ROCK-1 | 9, ER | - | - | + | + | + | NA | NA |
Gene product . | Patient . | Pre-BMT . | Pre-DLI . | 2 mo . | 4 mo . | 6 mo . | 1 y . | 2 to 2.6 y . |
|---|---|---|---|---|---|---|---|---|
| DHA | 2, ER | - | - | ++ | ++++ | +++ | +++ | ++ |
| DHA | 5, LR | - | - | - | - | + | ++ | ++ |
| BCMA | 2, ER | - | - | + | ++++ | +++ | ++ | + |
| BCMA | 5, LR | - | - | - | - | + | + | + |
| FLJ10330 | 2, ER | - | - | + | +++ | ++ | + | + |
| FLJ10330 | 5, LR | - | - | - | + | + | ++ | + |
| Homer-3 | 1, ER | - | - | NA | ++ | ++ | ++ | + |
| Homer-3 | 7, LR | - | - | NA | - | + | ++ | + |
| ROCK-1 | 4, LR | - | - | - | - | - | + | ++++ |
| ROCK-1 | 5, LR | - | - | - | - | + | + | + |
| ROCK-1 | 2, ER | - | - | + | +++ | ++ | + | + |
| ROCK-1 | 9, ER | - | - | + | + | + | NA | NA |
ER indicates early responder; LR, late responder; NA, sample not available; -, negative; +, weak; ++, moderate; +++,strong; and ++++, very strong.